RecruitingNot Applicable

NK Cell Therapy for Malignant Solid Brain Tumors

China27 participantsStarted 2026-04

Plain-language summary

This is a multi-center, open-label investigator-initiated trial (IIT) designed to evaluate the safety, tolerability, and feasibility of combined intracranial and intravenous administration of ex vivo expanded and activated natural killer (NK) cells in adult patients with malignant solid brain tumors who have failed standard treatment modalities. The primary objective is to determine the maximum tolerated dose (MTD) or maximum feasible dose (MFD) of the combined NK cell therapy. Secondary objectives include preliminary assessment of anti-tumor activity as measured by progression-free survival (PFS), overall survival (OS), objective response rate (ORR) per RANO criteria, and evaluation of the immunological effects of NK cell infusion in the tumor microenvironment and peripheral blood.

Who can participate

Age range18 Years – 70 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Male or female, age 18-70 years old (both ends included)
✓. At least one evaluable lesion with previous biopsy or pathohistologic confirmation of malignant central nervous system tumor, with imaging suggestive of continued progression or recurrence after comprehensive treatment
✓. Karnofsky Performance Status (KPS) ≥ 60%
✓. Life expectancy \> 4 weeks, and must be able to undergo an MRI with contrast
✓. Patients who completed radiotherapy or systemic therapies (including temozolomide/bevacizumab or other agents) for at least 4 weeks prior to enrollment. All prior treatment-related toxicities should be defined as ≤ grade 1 (except for toxicities such as alopecia or leukoplakia) according to the Common Terminology Standard for Adverse Events (CTCAE 6.0)
✓. Dexamethasone dose ≤ 4 mg/day or equivalent corticosteroid dose, or no dexamethasone administered
✓. Must have adequate organ and marrow function as defined below:
✓. No obvious hereditary diseases

Exclusion criteria

What they're measuring

Incidence of Adverse Events (AEs)

Timeframe: 3 months following NK cells administration

Incidence of Dose-Limiting Toxicities (DLTs)

Timeframe: 28 days following initial treatment with NK cells

Trial details

NCT IDNCT07552233

SponsorPeking University Third Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2030-12

Contact for this trial

Chenlong YANG, M.D., Ph.D.

(+86)-135-1108-7060 vik.yang@pku.edu.cn

View on ClinicalTrials.gov More Malignant Solid Brain Tumors trials